Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
21 December 2023 - 4:30PM
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the
Company”), a biotechnology company dedicated to developing disease
modifying treatments for neurodegenerative diseases, today
announced the appointment of Phillip Hains as the Company’s new
Chief Financial Officer (CFO), effective 31 January 2024.
Mr. Hains has served as the Company Secretary of
Alterity since 2014, and his experience includes almost 30 years in
corporate secretarial, accounting and general management through
professional services firm Acclime and predecessor firm The CFO
Solution.
The appointment of Mr. Hains follows the
resignation of Kathryn Andrews, who has been CFO since 2014. Ms.
Andrews has chosen to leave Alterity to pursue other interests and
will continue to support the Company during the transition.
David Stamler, M.D., Chief Executive Officer of
Alterity, commented, “On behalf of the Board of Directors and
management team, we would like to express our deep appreciation to
Kathryn for her valuable contributions to the Company during her
tenure as CFO, and we wish her well for the future. We look forward
to expanding our relationship with Phillip as we enter 2024 which
will be a pivotal year for us.”
About Alterity Therapeutics
Limited
Alterity Therapeutics is a clinical stage
biotechnology company dedicated to creating an alternate future for
people living with neurodegenerative diseases. The Company’s
lead asset, ATH434, has the potential to treat various Parkinsonian
disorders and is currently being evaluated in two Phase 2 clinical
trials in Multiple System Atrophy. Alterity also has a broad drug
discovery platform generating patentable chemical compounds to
treat the underlying pathology of neurological diseases. The
Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s
web site at www.alteritytherapeutics.com.
Authorisation & Additional
informationThis announcement was authorized by David
Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
AustraliaHannah
Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648
064
U.S.Remy Bernardaremy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking
statements" within the meaning of section 27A of the Securities Act
of 1933 and section 21E of the Securities Exchange Act of 1934. The
Company has tried to identify such forward-looking statements by
use of such words as "expects," "intends," "hopes," "anticipates,"
"believes," "could," "may," "evidences" and "estimates," and other
similar expressions, but these words are not the exclusive means of
identifying such statements.
Important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are described in the sections titled
“Risk Factors” in the Company’s filings with the SEC, including its
most recent Annual Report on Form 20-F as well as reports on Form
6-K, including, but not limited to the following: statements
relating to the Company's drug development program, including, but
not limited to the initiation, progress and outcomes of clinical
trials of the Company's drug development program, including, but
not limited to, ATH434, and any other statements that are not
historical facts. Such statements involve risks and uncertainties,
including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development,
testing, regulatory approval, production and marketing of the
Company’s drug components, including, but not limited to, ATH434,
the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate
therapeutic efficacy of the Company's drug compounds, including,
but not limited to, ATH434, that could slow or prevent products
coming to market, the uncertainty of obtaining patent protection
for the Company's intellectual property or trade secrets, the
uncertainty of successfully enforcing the Company’s patent rights
and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this
press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart
From Apr 2023 to Apr 2024